Adial Pharmaceuticals develops pharmaceuticals for addiction and associated complications, with a particular interest in non-opioid pain management candidates. AD04, the company's lead product, is a serotonin-3 antagonist currently undergoing Phase III clinical trials for alcohol use disorder treatment. The company is based in Charlottesville, Virginia, and was established in 2010.